| Comunicación Nº: 105 | English version  |
| Comunicación Nº: 105 | English version |
María José Fernández, Naomi Inuyama, Marlene Cabrera, Josefina Madera, María C. Robledo, Félix Contreras Mejuto
[Título] [Introducción] [Material y Métodos] [Resultados] [Iconografía] [Discusión]
|
|
1.- Allred DC. Prognostic and predictive factors in breast cancer assessed by inmunohistochemistry. In Breast Pathology Long Course. 86th Annual Meeting, USCAP, Orlando 1997.
2.- Fisher ER, Sass R, Fisher B, et al. Pathology findings from the national surgical adjuvant projet for Breast Cancer (protocol no 4). Discriminant for tenth year treatment failure. Cancer 1984;53:712-723.]
3.- Haybittle Jl, Blamey RW, Elston CW, et al. A prognostic index in primay breast cancer. Br J Cancer 1982;45:361-366.]
2.- Garne JP , Aspergren K, Linell F, Rank F, RanstamJ. Primary prognostic factors in invasive breast cancer with special reference to ductal carcinoma and histologic malignancy grade. Cancer 1994;73:1438-1448.]
2.- Esteban JM, Ahn C, Battifora H, Felder B. Predictive value of estrogen receptors evaluated by quantitative immunohistochemical analysis in breast cancer. Am J Clin Pathol 1994;102:S9-12.]
6.- Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomizad clinical trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 1992;339:1-15,71-85.]
7.- Henson DE, et al. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Summary. Arch Pathol Lab Med 1995;119:1109-1112.]
8.- Goldhirsh A, et al. International Consensus Panel on the Treatment of Primary Breast Cancer. Eur J Cancer 1995;31A:1754-1759.]
9.- American Society of Clinical Oncology. Clinical Practice Guidelines For The Use Of Tumor Markers In Breast And Colorectal Cancer. J Clin Oncol 1996;14:2843-2877.]
10.- van Agthoven T, Timmermans M, Foekens JA, et al. Differential expression of estrogen, progesterone, and epidermal growth factor receptors in normal, benign, and malignant human breast tissues using dual staining immunohistochemistry. Am J Pathol 1994;144:1238-1246.]
11.- Tandon AK, et al. HER2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989;7:1120-1128.]
12.- Lovekin C, et al. c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 1991;63:439-443.]
13.- Borj A, et al. HER2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990;50:4332-4337.]
14.- Haerslev T, Nedergaard L, Krag Jacobsen G. Immunohistochemical detection of c-erbB-2-oncoprotein in primary breast cancer and regional lymph node metastases. Diag Oncol 1994;3:177-182.]
15.- Levine AJ, et al. The P53 tumor suppressor gene. Nature 1991;351:453-546.]
16.- Barnes DM, Dublin EA, Fisher CJ, et al. Immunohistochemical detection of p53 protein in mammary carcinoma. An important new independent indicator of prognosis ?. Hum Pathol 1993;24:469-476.]
17.- McGuire WL, et al. Estrogen receptor variants in clinical breast cancer. Molecular Endocrinology 1991;5:1571-1577.]
18.- Fukua SAW, et al. Molecular aspects of estrogen receptor variants in breast cancer. Breast Cancer Res Treat 1995;35:233-241.]
19.- Mohammed RH, Lakatua DJ, Haus E, Yasmineh WJ. Estrogen and progesterone receptors in human breast cancer. Correlation with histology subtipe and degree of diferentiation. Cancer 1986;58:1076-1081.]
20.- Tsuda H, Hirohashi S, Shimosato Y, et al. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. A retrospective annalysis of 176 cases. Cancer 1990;65:1794-1800.
|
